A randomized, open-label assessment of response to various doses of atomoxetine in Korean pediatric outpatients with attention-deficit/hyperactivity disorder

Psychiatry Investigation

Volumn 8, Issue 2, 2011, Pages 141-148

  Cho, Soochurl ^a   Lee, Soyoung Irene ^b   Yoo, Hanik ^c   Song, Dong Ho ^d   Ahn, Dong Hyun ^e   Shin, Dong Won ^f   Yum, Sun Young ^g   Walton, Richard ^h   Mendez, Luis ⁱ  

^a Seoul National University Hospital   (South Korea)

^b Soonchunhyang University   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Hanyang University Medical Center   (South Korea)

^f School of Medicine   (South Korea)

^g ELI LILLY AND COMPANY   (United States)

^h ELI LILLY AUSTRALIA PTY LTD   (Australia)

ⁱ Eli Lilly Mexico   (Mexico)

Author keywords

ADHD; Atomoxetine; Dose response; Korea; Pediatric

Indexed keywords

ATOMOXETINE;

ADHD RATING SCALE IV; ADOLESCENT; ADULT; AGE; ARTICLE; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; CHILD; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHOOL CHILD; SIDE EFFECT; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

EID: 79960968540     PISSN: 17383684     EISSN: None     Source Type: Journal    
DOI: 10.4306/pi.2011.8.2.141     Document Type: Article

References (27)

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-948.
2. Cho SC, Kim BN, Kim JW, Rohde LA, Hwang JW, Chungh DS, et al. Full syndrome and subthreshold attention-deficit/hyperactivity disorder in a Korean community sample: comorbidity and temperament findings. Eur Child Adolesc Psychiatry 2009;18:447-457.
3. Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 2004;114:e541-e547.
4. Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004;13 Suppl 1:I102-I116.
5. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002;27:699-711.
6. Buitelaar JK, Danckaerts M, Gillberg C, Zuddas A, Becker K, Bouvard M, et al. A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry 2004;13:249-257.
7. Donnelly C, Bangs M, Trzepacz P, Jin L, Zhang S, Witte MM, et al. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2009;48:176-185.
8. Kratochvil CJ, Bohac D, Harrington M, Baker N, May D, Burke WJ. An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001;11:167-170.
9. Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002;41:776-784.
10. Kratochvil CJ, Michelson D, Newcorn JH, Weiss MD, Busner J, Moore RJ, et al. High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses. J Am Acad Child Adolesc Psychiatry 2007;46:1128-1137.
11. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001;108:E83.
12. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-1901.
13. Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001;11:251-265.
14. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63:1140-1147.
15. Gau SS, Huang YS, Soong WT, Chou MC, Chou WJ, Shang CY, et al. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2007; 17:447-460.
16. Takahashi M, Takita Y, Yamazaki K, Hayashi T, Ichikawa H, Kambayashi Y, et al. A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attentiondeficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2009; 19:341-350.
17. Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry 2007;41:222-230.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Press; 2000.
19. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale- IV. Checklist, Norms, and Clinical Interpretation. New York, NY: The Guilford Press; 1998.
20. Faries DE, Yalcin D, Harder D, Heiligenstein JH. Validation of the ADHD rating scale as a clinician-administered and scored instrument. J Atten Disord 2001;5:107-115.
21. So YK, Noh JS, Kim YS, Ko SG, Koh YJ. The reliability and validity of Korean parent and teacher ADHD rating scale. J Korean Neuropsychiatr Assoc 2002;41:283-289.
22. Williams DA. A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics 1971; 27:103-117.
23. Newcorn JH, Michelson D, Kratochvil CJ, Allen AJ, Ruff DD, Moore R. Atomoxetine Low-does Study Group. Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder. Pediatrics 2006;118:e1701-e1706.
24. Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL. Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy. Child Adolesc Psychiatry Ment Health 2008;2:25.
25. Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, et al. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord 2004;8:45-52.
26. Lee SI, Hong SD, Kim SY, Kim EJ, Kim JH, Park MK, et al. Efficacy and tolerability of OROS methylphenidate in Korean children with attentiondeficit/ hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:210-216.
27. Hammerness P, McCarthy K, Mancuso E, Gendron C, Geller D. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review. Neuropsychiatr Dis Treat 2009;5:215-226.